Compare DGX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGX | ROIV |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 20.7B |
| IPO Year | 1996 | 2021 |
| Metric | DGX | ROIV |
|---|---|---|
| Price | $189.81 | $28.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $214.38 | $28.94 |
| AVG Volume (30 Days) | 902.3K | ★ 4.3M |
| Earning Date | 04-21-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | ★ 13.78 | N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $11,035,000,000.00 | $29,053,000.00 |
| Revenue This Year | $7.53 | N/A |
| Revenue Next Year | $3.77 | $744.61 |
| P/E Ratio | $84.62 | ★ N/A |
| Revenue Growth | ★ 11.78 | N/A |
| 52 Week Low | $164.65 | $10.58 |
| 52 Week High | $213.50 | $30.33 |
| Indicator | DGX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 58.56 |
| Support Level | $187.13 | $27.00 |
| Resistance Level | $191.91 | $30.26 |
| Average True Range (ATR) | 4.44 | 0.90 |
| MACD | -0.47 | 0.06 |
| Stochastic Oscillator | 19.99 | 93.47 |
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.